Repligen Corporation (RGEN) Social Stream



Repligen Corporation (RGEN): $188.17

9.33 (+5.22%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RGEN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 379

in industry

REPLIGEN CORP (RGEN) Price Targets From Analysts

The tables below show the price targets and recommendations analysts covering RGEN.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-02 10 $368 $240 $312.555 $171.64 82.1%
2021-12-20 10 $368 $240 $315.888 $171.64 84.04%
2022-02-18 10 $368 $240 $310.333 $171.64 80.8%
2022-03-01 10 $368 $210 $281.444 $171.64 63.97%
2022-04-28 10 $330 $210 $257.666 $171.64 50.12%
2022-06-01 9 $330 $170 $249.888 $171.64 45.59%
2022-07-20 10 $330 $170 $246.888 $171.64 43.84%
2022-08-03 10 $330 $170 $248.555 $171.64 44.81%
2022-09-05 10 $330 $210 $267.444 $171.64 55.82%
2022-10-23 7 $320 $210 $257.125 $171.64 49.8%
2022-10-25 8 $320 $210 $257.125 $171.64 49.8%
2022-11-01 7 $320 $210 $254.625 $171.64 48.35%
2022-11-02 8 $270 $200 $240.5 $171.64 40.12%

The Trend in the Analyst Price Target


RGEN's average price target has moved down $40.94 over the prior 35 weeks.

Over the past 48 weeks, RGEN's average upside potential has been 43.21%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2022-01-07 10 368 240 310.333 206.79 50.07%
2022-03-01 10 368 210 281.444 194.06 45.03%
2022-06-01 9 330 170 249.888 166.70 49.9%
2022-07-20 10 330 170 246.888 176.70 39.72%
2022-09-05 8 330 210 267.444 210.34 27.15%

RGEN Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1.25 7 0 1 0 0 8

The Trend in the Broker Recommendations


Over the past 43 weeks, RGEN's average broker recommendation rating worsened by 0.09.

Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.

  • In the context of all US stocks, REPLIGEN CORP's average analyst price target is higher than 1958.3% of them.
  • In the context of Pharmaceutical Products stocks, REPLIGEN CORP's upside potential (average analyst target price relative to current price) is greater than 540.94% of them.
  • To contextualize these metrics, consider that out of Pharmaceutical Products stocks, REPLIGEN CORP's number of analysts covering the stock is greater than 1534.52% of them.
  • RGEN has a lower variance in analysts' estimates than -644.96% of Pharmaceutical Products stocks.

Stocks similar to REPLIGEN CORP in the Pharmaceutical Products industry regarding analyst recommendations and price targets are DNA, GMAB, and BGNE.

What is the outlook for RGEN? Use POWR Ratings for clearer insight into price direction.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6629 seconds.